Servier and CTI BioPharma agreed to expand their existing license and development collaboration agreement for pixantrone. The drug has been granted conditional marketing authorization from the European Commission for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma (NHL). As a specific post-authorization requirement, the product is currently being investigated in a phase III clinical trial to confirm the current indication and possibly to support broader indications. Servier will have rights in all markets except the US, where CTI BioPharma will retain the commercialization rights.